Pertumab
Therapeutic Segment:
HER2 directed monoclonal antibody
Generic Name:
Pertuzumab
Indication
- 420mg/14ml
Pertumab (Pertuzumab) is indicated:
• In combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
• In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
• In combination with Trastuzumab and chemotherapy for the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.